Regeneron Pharmaceuticals, Inc.
- REGN
- NASDAQ
- Biotechnology
- Ophthalmology Drugs (EYLEA)
- Immunology/Inflammation Drugs
$807.48
Today +3.25%Quote Oct 20, 2026, 08:00 PM UTC
+1.17%over the last month
Max drawdown −9.6%From 1-month high 0.0%3 months +24.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Where the money comes from
Q2 2026 revenue $4.29B
- Collaboration Revenue$2.46B57.2%
- Product$1.64B38.3%
- Product and Service, Other$193.3M4.5%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
15,410
Founded
1988
Market value
$83.13B
Quote Oct 20
Floor
$781.27
3.2% below price
Resistance
$809.25
0.2% above price
Price vs analyst targets
49 analysts
Lowest target
$750.00Highest target
$1030.00
$750.00Highest target
$1030.00
- Price $807.48
- Average target $856.80
- Analysts' target range
Analysts' average target sits about 6% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about REGNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free